Metabolic abnormalities: triglyceride and low-density lipoprotein.

Increased plasma triglyceride and reduced high-density lipoprotein cholesterol are key features of the metabolic syndrome. Although elevated low-density lipoprotein cholesterol is not an integral characteristic of this syndrome, there is commonly an increase in the proportion of small, dense low-density lipoprotein particles. Together, these abnormalities constitute the atherogenic dyslipidemia of the metabolic syndrome. This article reviews the pathophysiology of altered triglyceride and low-density lipoprotein metabolism in the metabolic syndrome, outlines the relationship of these lipoprotein abnormalities to increased risk of coronary heart disease,and highlights the application of this information to clinical practice. The role of reduced high-density lipoprotein in the metabolic syndrome is discussed elsewhere in this issue.

[1]  R. Krauss,et al.  Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 , 2002, Journal of Lipid Research.

[2]  R. Krauss,et al.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. , 1993, The American journal of medicine.

[3]  Paul T. Williams,et al.  Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Watts,et al.  Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). , 1993, Metabolism: clinical and experimental.

[5]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[6]  R. Krauss,et al.  Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. , 1987, American heart journal.

[7]  R. Krauss,et al.  Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.

[8]  P. Ridker,et al.  Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.

[9]  R. Krauss,et al.  Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J. Buring,et al.  Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. , 1997, Circulation.

[11]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[12]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[13]  D H Blankenhorn,et al.  Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. , 1990, Circulation.

[14]  S. Eisenberg,et al.  Plasma triglyceride determines structure-composition in low and high density lipoproteins. , 1984, Arteriosclerosis.

[15]  M. Taskinen,et al.  Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS) , 2003, Circulation.

[16]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[17]  R. Krauss,et al.  Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. , 1996, Circulation.

[18]  R. Krauss,et al.  Differences in receptor binding of LDL subfractions. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[19]  J. Hokanson,et al.  Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. , 1999, Circulation.

[20]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[21]  R. Krauss.  Dietary and genetic effects on low-density lipoprotein heterogeneity. , 2001, Annual review of nutrition.

[22]  M. Cnop,et al.  The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. , 2003, Diabetes.

[23]  David H. Blankenhorn,et al.  Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. , 1994 .

[24]  F. Sacks,et al.  Low-density lipoprotein size, pravastatin treatment, and coronary events. , 2001, JAMA.

[25]  G. Bondjers,et al.  Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. , 1996, Atherosclerosis.

[26]  D. B. Zilversmit.  Atherogenesis: a postprandial phenomenon. , 1979, Circulation.

[27]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[28]  C. Packard,et al.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. , 1991, The Journal of clinical investigation.

[29]  S. Yamashita,et al.  Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  G. Dagenais,et al.  Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease , 2001, Circulation.

[31]  M. Bond,et al.  Postprandial Triglyceridemia and Carotid Atherosclerosis in Middle‐Aged Subjects , 1992, Stroke.

[32]  G. Nelson.  Blood Constituents. (Book Reviews: Blood Lipids and Lipoproteins. Quantitation, Composition, and Metabolism) , 1972 .

[33]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[34]  P. Alaupovic.  The concept of apolipoprotein-defined lipoprotein families and its clinical significance , 2003, Current atherosclerosis reports.

[35]  R. Krauss,et al.  Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.

[36]  G. Dagenais,et al.  A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. , 2001, The Canadian journal of cardiology.

[37]  B. Howard,et al.  Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  M. Austin,et al.  Genetic and environmental influences on LDL subclass phenotypes , 1994, Clinical genetics.

[39]  T. Musliner,et al.  Lipoprotein substrates of lipoprotein lipase and hepatic triacylglycerol lipase from human post-heparin plasma. , 1979, Biochimica et biophysica acta.

[40]  R. Krauss,et al.  Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. , 1997, Circulation.

[41]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[42]  D. Waters,et al.  Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events , 1993, Circulation.

[43]  A. Thomas,et al.  Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[44]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[45]  A. Hamsten,et al.  Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. , 1993, Atherosclerosis.

[46]  H. Ginsberg.  New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism , 2002, Circulation.

[47]  M. Taskinen.  Insulin resistance and lipoprotein metabolism , 1995, Current opinion in lipidology.

[48]  E. Fisher,et al.  Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.

[49]  H. Hein,et al.  Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. , 1998, Circulation.

[50]  J. Bard,et al.  apoB-containing lipoprotein particles as risk factors for coronary artery disease. , 1991, Advances in experimental medicine and biology.

[51]  R. Havel,et al.  Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[52]  M. Laakso,et al.  Men and Women , 1901 .

[53]  C. Packard,et al.  Lipoprotein heterogeneity and apolipoprotein B metabolism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[54]  D. Freedman,et al.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.

[55]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[56]  J L Witztum,et al.  Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. , 1984, Proceedings of the National Academy of Sciences of the United States of America.